Drug Profile
Valanafusp alfa - ArmaGen Technologies
Alternative Names: AGT-181; cTfRMAb-IDUA murine fusion protein; HIRMAb-IDUA; IgG-alpha-L-iduronidase fusion protein; IgG-IDUA fusion protein; Recombinant human insulin receptor monoclonal antibody-fused alpha-L-iduronidase; Valanafusp; Valanafusp Alpha - ArmaGenLatest Information Update: 29 Sep 2021
Price :
$50
*
At a glance
- Originator ArmaGen Technologies
- Class Immunoglobulin fusion proteins; Monoclonal antibodies
- Mechanism of Action Iduronidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Mucopolysaccharidosis I
Most Recent Events
- 29 Sep 2021 Phase II development for Mucopolysaccharidosis I (In children) is still ongoing in Brazil (IV) (ArmaGen Technologies website, September 2021)
- 08 Sep 2021 No development reported - Phase-I/II for Mucopolysaccharidosis I in USA (IV)
- 08 Sep 2021 No development reported - Phase-II for Mucopolysaccharidosis I (In children) in Brazil (IV)